Cargando…

Distinct profile of CD34(+) cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease

BACKGROUND: Myelofibrosis (MF) is a clonal disorder of hemopoietic stem/progenitor cells (HSPCs) with high prevalence in elderly patients and mutations in three driver genes (JAK2, MPL, or CALR). Around 10–15% of patients are triple-negative (TN) for the three driver mutations and display significan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forte, Dorian, Barone, Martina, Morsiani, Cristina, Simonetti, Giorgia, Fabbri, Francesco, Bruno, Samantha, Bandini, Erika, Sollazzo, Daria, Collura, Salvatore, Deregibus, Maria Chiara, Auteri, Giuseppe, Ottaviani, Emanuela, Vianelli, Nicola, Camussi, Giovanni, Franceschi, Claudio, Capri, Miriam, Palandri, Francesca, Cavo, Michele, Catani, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849077/ https://www.ncbi.nlm.nih.gov/pubmed/33522952 http://dx.doi.org/10.1186/s13046-020-01776-8

Ejemplares similares

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
por: Sollazzo, Daria, et al.
Publicado: (2016)

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34(+) Cells
por: Forte, Dorian, et al.
Publicado: (2018)

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
por: Sollazzo, Daria, et al.
Publicado: (2016)

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera
por: Barone, Martina, et al.
Publicado: (2021)

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
por: Barone, Monica, et al.
Publicado: (2021)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms
por: Forte, Dorian, et al.
Publicado: (2020)

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
por: Auteri, Giuseppe, et al.
Publicado: (2021)

The “Vesicular Intelligence” Strategy of Blood Cancers
por: Forte, Dorian, et al.
Publicado: (2021)

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2022)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
por: Catani, Lucia, et al.
Publicado: (2021)

Circulating miR-122-5p, miR-92a-3p, and miR-18a-5p as Potential Biomarkers in Human Liver Transplantation Follow-Up
por: Morsiani, Cristina, et al.
Publicado: (2023)

Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
por: Auteri, Giuseppe, et al.
Publicado: (2023)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
por: Cattaneo, Daniele, et al.
Publicado: (2022)

Circulating perilipin 2 levels are associated with fat mass, inflammatory and metabolic markers and are higher in women than men
por: Conte, Maria, et al.
Publicado: (2021)

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2017)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
por: Palandri, Francesca, et al.
Publicado: (2012)

Circulating miR‐19a‐3p and miR‐19b‐3p characterize the human aging process and their isomiRs associate with healthy status at extreme ages
por: Morsiani, Cristina, et al.
Publicado: (2021)

The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling
por: Forte, Dorian, et al.
Publicado: (2016)

Cell‐free DNA as a biomarker of aging
por: Teo, Yee Voan, et al.
Publicado: (2018)

PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
por: Sartor, Chiara, et al.
Publicado: (2023)

The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates
por: Franceschi, Claudio, et al.
Publicado: (2018)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

Stem cells and stem cell-derived extracellular vesicles in acute and chronic kidney diseases: mechanisms of repair
por: Tetta, Ciro, et al.
Publicado: (2020)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Cattaneo, D., et al.
Publicado: (2022)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
por: Tiribelli, Mario, et al.
Publicado: (2019)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

Serum or Plasma (and Which Plasma), That Is the Question
por: Vignoli, Alessia, et al.
Publicado: (2022)

Salivary Extracellular Vesicle-Associated exRNA as Cancer Biomarker
por: Chiabotto, Giulia, et al.
Publicado: (2019)

Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability
por: Forte, Dorian, et al.
Publicado: (2023)

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
por: Ciciarello, Marilena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ukre370rbv5pv558hvr4b5m8fb